<SEC-DOCUMENT>0001193125-24-217135.txt : 20241016
<SEC-HEADER>0001193125-24-217135.hdr.sgml : 20241016
<ACCEPTANCE-DATETIME>20240911130557
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-24-217135
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240911

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Legend Biotech Corp
		CENTRAL INDEX KEY:			0001801198
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
		BUSINESS PHONE:		732-317-5050

	MAIL ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g903878g02a90.jpg" ALT="LOGO" STYLE="width:1.56458in;height:0.625694in;">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Ballantyne</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(703) 456-8084</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>mballantyne@cooley.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">VIA EDGAR</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;11, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities&nbsp;&amp; Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, NE
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Attn:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jessica Dickerson </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Tim Buchmiller </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Legend Biotech Corporation </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">20-F</FONT> for Fiscal Year Ended December&nbsp;31, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Filed March&nbsp;19, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-39307</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of our client Legend Biotech Corporation (the &#147;<B>Company</B>&#148;), an exempted company incorporated under the laws of the
Cayman Islands, we submit to the staff (the &#147;<B>Staff</B>&#148;) of the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) this letter setting forth the Company&#146;s responses to the comments contained in the Staff&#146;s
letter dated September&nbsp;4, 2024 on the Company&#146;s Form <FONT STYLE="white-space:nowrap">20-F</FONT> for its fiscal year ended December&nbsp;31, 2023 filed on March&nbsp;19, 2024 (the
&#147;<B><FONT STYLE="white-space:nowrap">20-F</FONT></B>&#148;). Each of the Staff&#146;s comments are repeated below in bold, followed by the Company&#146;s response to the comments. All capitalized terms used but not defined in this letter,
including references to &#147;China&#148;, shall have the meaning ascribed to such terms in the <FONT STYLE="white-space:nowrap">20-F.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for Fiscal Year Ended December&nbsp;31, 2023 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Item 3. Key Information </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Our Holding Company Structure and China Operations, page 3 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. We note the changes you made to your disclosures in this section, as compared to your prior annual reports, regarding certain operational and legal risks
associated with your operations in China. Specifically, we note the removal of some of your disclosures regarding the oversight, discretion, control, and influence that PRC governmental authorities have on your operations, as well as the removal of
other disclosures regarding the uncertain, inconsistent, and unpredictable nature of the PRC legal system and the associated risks. We further note similar changes in your risk factor summary on page 8 and in your risk factors on pages 59 and 60.
However, it is unclear to us that there have been changes in the regulatory environment in the PRC since our review of your prior annual report, completed on September&nbsp;15, 2023, warranting these revised disclosures. The Sample Letter to
China-Based Companies, available on our website, sought specific disclosures regarding the risk that the PRC government may intervene in or influence your operations at any time, or may exert control over operations of your business, which could
result in a material change in your operations and/or the value of your securities. We do not believe that your revised disclosures convey the same risks. In future filings, please restore your disclosures in these areas to the disclosures as they
existed in prior filings. In doing so, we remind you that, pursuant to federal securities rules, the term &#147;control&#148; (including the terms &#147;controlling,&#148; &#147;controlled by,&#148; and &#147;under common control with&#148;) means
&#147;the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract, or otherwise.&#148;</B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Response to Comment 1: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company respectfully submits that it will restore its disclosures in the areas identified by the Staff in its future filings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. We note that, as compared to your prior annual reports, you no longer discuss the Holding Foreign Companies Accountable Act. In future filings, please
disclose in this section the location of your auditor&#146;s headquarters, as well as whether and how the Holding Foreign Companies Accountable Act, the Accelerating Holding Foreign Companies Accountable Act, and related regulations will affect your
company. To the extent these acts do not apply to or otherwise impact you, please so state. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Response to Comment 2: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company respectfully submits that it will disclose the location of its auditor&#146;s headquarters and how the Holding Foreign Companies Accountable Act,
the Accelerating Holding Foreign Companies Accountable Act, and related regulations will affect the Company or do not apply to or otherwise impact the Company in its future filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&#8195;&#8195;*&#8195;&#8195;* </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions regarding this submission, please contact the undersigned at (703)
<FONT STYLE="white-space:nowrap">456-8084</FONT> or mballantyne@cooley.com or Divakar Gupta at (212) <FONT STYLE="white-space:nowrap">479-6474</FONT> or dgupta@cooley.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thank you for your time and attention. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Mark Ballantyne</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Mark Ballantyne</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ying Huang, Chief Executive Officer </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lori Macomber, Chief Financial Officer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">James Pepin, General Counsel </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Legend Biotech Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Divakar Gupta, Partner </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Cooley
LLP </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g903878g02a90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g903878g02a90.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0"F17AI9@  24DJ  @    & #X!!0 "
M    5@   #\!!0 &    9@    $#!0 !    E@   !!1 0 !     0   !%1
M!  !    (RX  !)1!  !    (RX        F>@  H(8! (2   "@A@$  /H
M *"& 0#H@   H(8! #!U  "@A@$ 8.H  *"& 0"8.@  H(8! ' 7  "@A@$
MH(8! (^Q  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:
M'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-
M#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C+_P  1"  [ )0# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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MB2,S?,W7'#?Q#\Z4:C;M)6-*^748TG4HUE.VZV?ZG>T445J>2%%%% !1110
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M?>NR\0Z[;>'=)DO[G+8.V.,'F1CT _ST%>8_%...T\56ES;D)</ KN5Z[@Q
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#G__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
